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Background: Following the introduction of the ILAR criteria for juvenile idiopathic arthritis, juvenile psoriatic arthritis
(JPsA) has become a better recognized category within the inflammatory arthritides of childhood. There are fewer
reports describing the characteristics and long-term outcome of patients with JPsA than other subtypes of JIA.
The aim of our study was to determine the long-term outcome and clinical course of patients with juvenile psoriatic
arthritis (JPsA) and to define subgroups of JPsA.
Methods: Clinical records of all patients meeting criteria for JPsA were reviewed and divided into 4 groups depending
on their clinical features and onset type. Patient characteristics and clinical features at onset and during follow-up were
determined.
Results: The cohort consisted of 119 patients: 65 with oligoarticular-onset (55%; persistent 44 and extended 21),
34 (29%) with RF(−) and 4 (3%) RF(+) polyarticular and 16 (13%) enthesitis-related arthritis (ERA). At diagnosis patients
with ERA were oldest and more commonly male (p=0.001 and =0.01 respectively). Patients with a polyarticular course
had more involvement of small joints of the hands and wrist when compared to patients with persistent oligoarticular
and ERA (p<0.001) while patients with ERA had more hip and sacroiliac arthritis (p<0.001 for both). Nail changes were
seen in 66 patients (57%) and were associated with DIP involvement (p=0.0034).
Outcome: Time to first inactive disease on, but not off, therapy was significantly longer among patients with
polyarticular course when compared to oligoarticular and ERA (p=0.016 and p=0.48 respectively). Patients with
polyarticular course more frequently had contractures during follow-up than other groups (p=0.01).
Conclusion: The long-term outcome of with JPsA was generally good. Patients with JPsA did not appear to form
distinct sub-group of patients but rather resembled JIA patients with onset types without psoriasis.Background
Following the introduction of the ILAR criteria for juve-
nile idiopathic arthritis, juvenile psoriatic arthritis (JPsA)
has become a better recognized category within the in-
flammatory arthritides of childhood. Patients defined as
having JPsA, within the ILAR classification, must have a
persistent arthritis of greater than 6 weeks with onset of
the arthritis prior to age 16 and either the presence of a
psoriatic rash, or in the absence of rash, at least 2 of the* Correspondence: earl.silverman@sickkids.ca
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distribution, and reproduction in any mediumfollowing minor criteria: first degree relative with psoriasis,
nail pitting or onycholysis, and dactilytis [1]. Prior to the
ILAR criteria another classification scheme was used: the
Vancouver Criteria [2]. This classification scheme differs
from the ILAR classification by the following additional
minor criteria: a) the psoriasis could be in first-degree or
second-degree relative and b) the presence of a psoriatic-
like rash is sufficient for classification of JPsA. According
to the Vancouver criteria definite JPsA is defined as arth-
ritis with either psoriasis or at least 3 minor criteria; pa-
tients with only 2 minor criteria were defined as probable
JPsA. This latter category is not present in the ILAR
Classification.
There are fewer reports describing the characteristics
and long-term outcome of patients with JPsA than other
subtypes of JIA and no report solely using the ILARntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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overlapping subsets of patients or were small cases series
[2-13]. As more than one classification system for JPsA
has been used, it can be confusing to compare different
studies and, as recently as 2008, no single classification
was agreed upon or universally accepted [12].
The aims of this study were to determine the long-
term joint outcome and functional status of children
with JPsA and to define subgroups of JPsA.
Patients and methods
Patients
The charts of all 122 patients who met the Vancouver cri-
teria (definite or probable) [2] or ILAR criteria [1] for JPsA,
and who were diagnosed and followed at the Rheumatology
Clinic at The Hospital for Sick Children (SickKids),
Toronto between 1985 and 2005 were reviewed.
Data collection presentation and follow-up
Patients′ charts were reviewed for the following clinical
variables at presentation and at each follow-up visit:
height, weight, joint involvement, presence or absence of
symmetric arthritis, nail pits, dactylitis, presence of
psoriatic rash or psoriasis-like rash, and uveitis. All me-
dications, including corticosteroid joint injections, were
recorded for each visit. Patient visits at presentation 1, 3,
6, 12, 36, and 60 months following the first presentation
and every 5 years thereafter were used. Serologic va-
riables studied were: a) Rheumatoid Factor (RF) as
detected by latex agglutination; a positive test result was
defined as titer ≥ 2 on at least two occasions (data were
available on 88% of patients); b) Anti-nuclear antibody
(ANA) as detected by immunofluorescent microscopy
using the Hep2 cell line. A positive result was defined as
a titer ≥ 1:40 on at least one occasion (data were avai-
lable on 88% of patients); and c) HLA B-27 antigen (data
were available on 44.5% of patients).
The following complications were recorded at each
visit: presence of a joint contracture, and presence of
leg-length discrepancy. The Childhood Health Assess-
ment Questionnaire (CHAQ) [14] was available at last
follow-up in 73.1% of the patients. For patients with
uveitis the final visual acuity and ocular complications
were obtained [15].
Definitions
The diagnosis of psoriasis was made by a rheumatolo-
gist and/or dermatologist. Rashes thought likely (but
not definitively) to represent psoriasis were considered
psoriasis-like.
Polyarticular involvement was defined by the involve-
ment of ≥ 5 joints cumulatively at any point over the
course of study. Oligoarticular arthritis was defined as
involvement of < 5 joints: a)persistent oligoarthritis- < 5joints throughout the disease course; or b)extended- ≥ 5
were involved at any point after the initial 6 months.
Enthesitis was defined as tenderness at a tendinous, liga-
mentous, capsular, or fascial insertion into bone.
Dactylitis was defined as digital swelling extending be-
yond the margins of the joints. Patients with dactylitis
were not considered to have involvement of the corres-
ponding joint(s) with arthritis unless it was specifically
documented.
Symmetric arthritis was defined as being present if
the number of affected joint pairs divided by the
total number of joints involved was ≥50%. The fol-
lowing 11 joint pairs were used: shoulders, elbows,
wrists, any metacarpophalangeal (MCP), any pro-
ximal interphalangeal (PIP) of the hand, hips, knees,
ankles, any metatarsophlangeal (MTP), any PIP) of
the foot, and the temporomandibular (TMJ) [16].
Inactive disease was defined as absence of clinically evi-
dent synovitis and enthesitis for a minimum of 3 months.
Patients may have been receiving medication at the time
of meeting the criteria for inactive disease.
Patients were excluded from inactive disease analysis if
they were followed for < one year, or if insufficient data
for the
Patients who were diagnosed with other rheumatic
diseases such as systemic lupus erythematosus or had
features of systemic JIA were excluded from the study.Definition of sub-types
Patients were divided into 4 groups depending on their
clinical features: a) Oligoarticular course; b) RF negative (−)
polyarticular course (divided into extended oligoarticular
and polyarticular-onset; c) RF positive (+) polyarticular
course; and d) enthesitis-related arthritis (ERA) (modified
tILAR definition as psoriasis could be present) using ILAR
criteria [1].Statistic methods
All descriptive data were expressed as the mean ± stan-
dard deviation (SD). Comparisons between groups were
performed using Chi-Square Tests with Bonferroni correc-
tions when applicable and ANOVA test with Tukey–
Kramer Honestly Significant Difference correction for
continuous variables (comparisons were for the following
4 groups: ERA, persistent oligoarticular, extended oligo-
articular, and RF- polyarticular, and not polyarticular
course). Kaplan-Meirer survival analysis was performed
for time to first inactive disease, both on or off therapy,
and was compared between the groups – the p value was
calculated using Log Rank Chi-Square Test.
Comparisons of the continuous variables at presenta-
tion and at last follow-up were performed using paired
t-test analysis.
Butbul Aviel et al. Pediatric Rheumatology 2013, 11:11 Page 3 of 8
http://www.ped-rheum.com/content/11/1/11Institutional Review Board approval was obtained for
this study (no.0019980177).Results
The initial cohort consisted of 122 patients with JPsA:
three were excluded due to insufficient follow-up data.
The study cohort consisted of 119 patients – 109 pa-
tients had definite and 10 patients had probable JPsA by
the Vancouver Criteria [2]. Ninety-nine of also fulfilled
the ILAR criteria for JPsA [1]. The other 20 patients
would have been excluded from the study if only ILAR
criteria were used: a) 4 patients tested positive for
rheumatoid factor on at least two occasions; and b) 16
patients also met the criteria for ERA. Ninety-nine pa-
tients had a definite psoriatic rash and 4 patients had a
psoriatic-like rash. Thirty-three patients were diagnosed
with psoriasis before the onset of arthritis (median 2.5
years mean of 3.4±3.1 years), 30 patients at the same
time and in 40 patients the diagnosis of psoriasis
was made after the onset of arthritis (median 2.9 mean
of 4.2±4.0 years).
At the time of the first visit 93 patients fulfilled the
Vancouver criteria with 87 patients having definite and 6
patients probable JPsA. Eighty-one of the 93 patients
also fulfilled the ILAR criteria for JPsA at presentation
(the other 12 met the criteria for more than one JIA
sub-type). Ethnicity data was available for 56 patients
(49%). The vast majority of patients (49/56) were of
European ancestry (87.5%), one patient was African-
Canadian, one Chinese-Canadian and 5 patients had a


















Family history of psoriasis
(percentage)
8 (50) 26 (59)
Number of patients with positive
ANAa
1/14 14/40
Number of patients with positive
HLA-B27
6/15 3/18
Number of patients with
asymptomatic uveitis(acute uveitis)
0 (5) 6 (0)
Number of patients with dactylitis 3 11
#- values are shown as mean plus/minus standard deviation.
a=Positive anti-nuclear antibody (ANA) defined as at least one positive ANA result.
* Anova.
**chi-square analysis.Demographic data
The mean age at presentation was 8.0±4.4 years with 80
females (67%) and 39 males (33%) (Table 1). The mean
age at diagnosis was significantly lower for females with
JPsA when compared to males (median 6.7 vs. 9.4 years)
(mean 7.3±4.4 vs. 9.3±4.1 years) (p=0.03). The duration
of follow-up ranged from 1 month to 16.8 years. There
were no significant differences in the follow-up times
among the groups (Table 1).
The most common type of arthritis found was
oligoarticular-onset in 65 patients (55%)- 44 patients
(68%) had a persistent oligoarticular course and 21
(32%) had extended oligoarticular arthritis (polyarticular
course). The median time to extension was 2.9 years
(mean 3.1±2.3). Overall, 55 patients (46%) had polyarticular
course arthritis (excluding patients with ERA). Features of
ERA were present in 16 patients (14%): 7 patients had ≥ 5
joints during the disease course and 9 patients <5 joints.
The least common course-type was RF+ polyarticular
course, which was found in only 4 patients (3%) (not fur-
ther analyzed because of sample size).
A positive family history of psoriasis was found in 68
patients: 40 had a first-degree relative with psoriasis and
28 had second-degree relative.Clinical findings
Joint involvement
a) Large joints The most commonly involved large
joints at both presentation and during the course of the
disease were the knee (67%) and ankle (23% of patients)













1:1.6 1:3.9 2.5:1 2:1 0.006*
6.6±5 (3.5) 7.4±4.2 (7.2) 7.1±4.5 (5.8) 8±4.4 (8.1) 0.003**
7.2±0.9 (6) 6.6±0.7 (6.5) 6.8±4.6 (6.1) 6.2±4.1 (5.3) 0.3**
12 (57) 22 (65) 34 (62) 68 (59) 0.8**
11/19 13/29 24/49 39/103 0.07**
0/8 1/8 1/17 10/50 0.0001*
3 (0) 4 (0) 7 (0) 13 (5) 0.6*
11 11 22 36 0.09*












Knee 6 (37.5) 32 (72.7) 15 (71) 24 (70) 39(70) 77 (66.9) 0.06
Ankle 5 (31.2) 9 (20.4) 7 (33) 17 (50) 24(44) 38 (33.0) 0.05
Subtalar 2 (12.5) 3 (6.8) 3 (14.3) 5 (14.7) 8(14.5) 13 (11.3) 0.7
Hip 5 (31.2) 5 (11.4) 0 (0) 0 (0) 0(0) 10 (8.7) 0.0012
Shoulder 1 (6.2) 1 (2.3) 1 (4.7) 3 (8.8) 4(7) 6 (5.2) 0.63
Elbow 1 (6.2) 3 (6.8) 3 (14.3) 9 (26.5) 12(21.8) 16 (13.9) 0.07
Wrist 1 (6.2) 4 (9.0) 7 (33) 13 (38.2) 20(36.3) 25 (21.7) 0.038
MCP 2 (12.5) 3 (6.8) 2 (9.5) 12 (35.3) 14(25.4) 19 (16.5) 0.005
PIP of Hand 3 (18.7) 6 (13.6) 2 (9.5) 18 (52.9) 20(36.3) 29 (25.2) 0.0002
DIP of Hand 2 (12.5) 2 (4.6) 0 (0) 6 (17.6) 6(10.9) 10 (8.7) 0.08
TMJ 1 (6.2) 2 (4.6) 6 (17.6) 6 (17.6) 6(10.9) 9 (7.8) 0.07
Cervical
spine
0 (0) 2 (4.6) 0 (0) 0 (0) 1(1.8) 2 (1.7) 0.50
Sacroiliac 5 (31.2) 0 (0) 0 (0) 0 (0) 0(0) 5 (4.3) <0.0001
Any small
joint*
6 (37.5) 12 (27.3) 5 (24) 25 (73.5) 30(54.5) 48 (41.7) 0.0001
MTP metatarsal phalangeal joint.
PIP proximal interphalangeal joint.
MCP metacarpal phalangeal joint.
DIP distal interphalangeal joint.
*any small joint refers to: PIP of hands and feet, MCP, and MTP.
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were found for: hip (highest in ERA) (p=0.0012), ankle
(highest in RF- polyarticular) (p=0.05) and wrist (lowest
in ERA) (p=0.038) (Table 2). During follow-up, involve-
ment of the hip (p=0.05), wrist (p=0.0004), and elbow
(p=0.0002) differed among the groups (Table 3).b) Small joints At presentation there was a statistically
significant difference for any small joint involvement
(p=.0005) and for MCP (p=0.005) and PIP of the hands
(p=0.0002) (all highest in RF- polyarticular group)
(Table 2). During the follow-up period again there was a
statistically significant difference for any small joint
(p<0.0001) and for PIP of the hands (p=0.0002) and
MCPs (all highest in RF- polyarticular group) (p=0.005)
(Table 3).
At presentation there was no significant difference for
the frequency of DIP involvement but during follow-up
DIP involvement differed (Table 3).TMJ
During the follow-up period we found that there was a
statistically significant higher percentage of TMJ in-
volvement in patients with RF- polyarticular and ex-
tended oligoarticular disease as compared to the ERA
and persistent oligoarticular groups but at presentation
(Tables 2 and 3).Sacroiliac (SI) joint
Five patients with ERA (31%) had SI joint involvement
at presentation and 7 patients (44%) during the disease
course. SI joint involvement was not seen in any of the
other patients at presentation, and was only rarely seen
during the follow–up in these patients (Tables 2 and 3).Symmetry of joint involvement
At presentation 45 patients of the total cohort (39%) had
symmetric joint involvement and 52 patients (45%) dur-
ing follow-up. There was an increased prevalence of
symmetric arthritis for the RF- polyarticular and the ex-
tended oligoarticular groups compared to the persistent
oligoarticular and ERA groups but not between the RF-
polyarticular and extended oligoarticular groups (data
not shown).Other features
There was no difference in the percentage of patients
with dactylitis among the groups (p=0.14) (Table 1). At
presentation patients with younger age of onset tended
to have more dactylitis (R2=0.025; p=0.06).
Nail changes secondary to psoriasis was seen in 66 of
the cohort (57%) with nail pitting seen in 64 patients
and onycholysis in only 2 patients. Nail pitting was sig-
nificantly associated with a higher incidence of DIP in-
volvement at presentation but not during follow-up
(p=0.0034 and p=0.6 respectively).
















34 (77.2) 18 (85.7) 26 (76.4) 44(80) 90 (78.3) 0.8
Ankle 9 (56.0) 20 (45.0) 16 (76.2) 21 (62.0) 37(67) 66 (57.4) 0.1
Subtalar 4 (25.0) 4 (9.0) 9 (26.5) 7 (33.0) 16(29) 24 (20.1) 0.09
Hip 7 (43.7) 6 (13.6) 4 (19.0) 5 (14.7) 9(16.3) 22 (19.1) 0.05
Shoulder 2 (12.5) 2 (4.5) 3 (14.3) 8 (23.5) 11(0.2) 15(13.0) 0.1
Elbow 2 (12.5) 6 (13.6) 9 (43.0) 19 (56.0) 28(50.9) 36 (31.0) 0.0002
Wrist 3 (18.7) 13 (29.5) 13 (61.9) 23 (67.6) 36(65.4) 52 (45.2) 0.0004
MCP 3 (18.7) 5 (11.4) 9 (42.9) 21 (61.7) 30(54.5) 38 (33.0) <0.0001
PIP of Hand 5 (31.0) 7 (15.9) 12 (42.8) 26 (76.5) 38(69) 51 (43.5) <0.0001
DIP of Hand 3 (18.7) 3 (6.8) 5 (23.8) 10 (29.4) 15(27.2) 21 (18.3) 0.07
TMJ 1 (6.2) 5 (11.4) 7 (33.3) 10 (29.4) 17(30.9) 23 (20.0) 0.04
Cervical
spine
0 (0) 4 (9.0) 3 (14.3) 5 (14.7) 8(14.5) 12 (10.3) 0.4
Sacroiliac 7 (43.7) 3 (6.8) 1 (5.0) 2 (6.0) 3(5.4) 13 (11.3) 0.0002
Any small
joint **
7 (43.7) 12 (27.2) 3 (14.3) 4 (11.8) 48(87.3) 67 (58.0) <0.0001
MTP metatarsal phalangeal joint.
PIP proximal interphalangeal joint.
MCP metacarpal phalangeal joint.
DIP distal interphalangeal joint.
* values are shown as number with percentage in brackets.
**any small joint refers to: PIP of hands and feet, MCP, and MTP.
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A positive ANA was associated with younger age
(R2=0.07; p=0.0027) (Odds ratio 0.862 with confidence
intervals of 0.78 -0.953).
There was a statistically significant difference for the
presence of HLA-B27 among the groups (P<0.0001).Treatment
All patients were treated with NSAIDs at presentation
and/or during follow-up. Methotrexate was the most com-
monly used second-line agent and was significantly more
frequently used in patients with polyarticular course as
compared persistent oligoarticular patients (p=0.01) but
not to patients with ERA (Table 4). Within polyarticular
course patients there was no difference in methotrexate
use between RF- polyarticular and extended oligoarticular
patients (data not shown). There was a significant differ-
ence in the use of other second-line agents when the
polyarticular course group were compared to the persistent
oligoarticular (45% vs. 23%, p= 0.02) but not when com-
pared to the ERA group or between the 2 polyarticular
course groups (data not shown) (Table 4). There were no
differences in the use of oral prednisone and anti-
tumour necrosis factor (TNF) therapy when comparing
the polyarticular course group to the other groups, al-
though patients with extended oligoarticular arthritiswere significantly more likely to be treated with an anti-
TNF agent than the other groups (24% vs. 6% p=0.05).
Outcome measures
Twenty-one (18%) of the patients had a joint contracture
during the course of their disease: small joint of the
hand (10 patients), elbow in 5, and wrist and hip in 2 pa-
tients each. Seven patients had deviation of the jaw and
one patient had restricted range of motion of the neck
(Table 5). We found that patients with RF- polyarticular
and extended oligoarticular course were more likely to
have a contracture compared to the other groups at
presentation but not during the disease course (Table 5).
A leg-length discrepancy was found in only 3 patients
(3%) at last follow-up with no significant difference
among the groups.
A CHAQ score was available in 86 patients (75%) at
the last visit after a mean time of arthritis of 6.3±4.3
years. The mean CHAQ scores were similar among the
groups (Table 4).
Assessment of inactive disease was available for 109
patients. All but 7 patients (4 with polyarticular, 2 with
oligoarticular and 1 with ERA) had inactive disease at
least once during the follow-up period. At the last
follow-up 63 patients (55%) had inactive disease; there
were no differences among the groups for percentage of
patients with inactive disease on medication. At the last
follow-up 33 patients (30%) were inactive off all














Methotrexate 4 (25.0) 8 (18.2) 10(47.6) 13(38.2) 23 (41.8) 35 (22.6) 0.03
Anti-TNF
agent
2 (12.5) 1 (2.3) 6(28.5) 2(5.9) 7* (12.7) 10 (8.7) 0.16
Etanercept 1 (6.2) 1 (2.3) 5(23.8) 2(5.9) 7 (12.7) 9 (7.8) 0.15
Infliximab 1 (6.2) 0 (0) 1(4.7) 0(0) 1 (1.8) 2 (1.7) 0.26
Any DMARD 4 (25.0) 10 (22.7) 11(52.4) 14(41.2) 25 (45.4) 39 (33.9) 0.04
Prednisone 2 (12.5) 1 (2.3) 4(19) 3(8.8) 7 (12.7) 10 (8.7) 0.15
* one patient was treated with both etanercept and infliximab.
DMARD: Disease-Modifying Anti-Rheumatic Drug.
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groups.
Using Kaplan-Meir survival analysis, the median time
to inactive disease on therapy for the total cohort was
1.23 years (mean 2.1 ±0.3 years) and the median time to
inactive disease off therapy was1.8 years (mean 2.5±0.26
years) (Figure 1). There was no significant difference
among the groups in mean time to first inactive disease
on therapy (p=0.4) or off therapy (p=0.2) (Figure 1).Growth
Height and weight data were available at the first and
last visit in 53 patients (46%). The median percentile for
weight at last follow-up at 68.5 (mean 65.2±26.4) was
significantly higher when compared to the first visit that
was 57.6 (mean 54.2±31.3) (p=0.0014) with no signifi-
cant differences among the groups.
There was no significant change in the height percen-
tiles from the first visit to the last visit (medians 54.9 vs.
61.8) (means 55.7±29.4 vs. 53.6±29.6) (p=0.77).Uveitis
Chronic uveitis occurred in 13 patients (11%) of the total
cohort. There was no significant difference among the
groups (p=0.63). Acute uveitis developed in 5 patients









Contracture at any time 0 5 8(38)
Contracture at last visit 0 2 4(19)
Leg-length discrepancy 2 9 2(9.5)
Time to last CHAQ*#




Value of last CHAQ 0.25±
0.40
0.23±0.40 0.23±0.
* CHAQ- Childhood Health Assessment Questionnaire.
#- values are shown as mean plus/minus standard deviation.Discussion
It is recognized that patients with JPsA may be a hetero-
geneous group of patients who may present with fea-
tures of similar to the other JIA subtypes. Two different
classification systems of JPsA have been proposed, with
the ILAR classification gaining increasing usage [1,2].
Our findings are consistent with previous studies that
suggested patients with JPsA comprise distinct popula-
tions that can be differentiated by the age of onset and
clinical features [6,11,17,18]. These results are similar to
studies of adult patients with PsA that demonstrated
subsets based on number of and/or location of joint in-
volvement, symmetry and features of spondylitis [19-23].
The diagnosis of JPsA frequently occurs in patients
who had been previously diagnosed with other forms of
JIA with development of the diagnostic rash month to
years later. We found that 1/3 of patients were diag-
nosed with another JIA sub-type prior to the diagnosis
of JPsA after a mean of 4.2 years. In most of these pa-
tients a diagnosis of JPsA was not suspected based on
clinic findings although some had a family history of
psoriasis. In addition 3 patients with systemic JIA and
psoriasis (data not shown), and 4 with RF+ polyarticular
JIA and psoriasis could not be clinically differentiated
from others with systemic or RF+ polyarticular JIA.
The most common course of arthritis found in the co-
hort was polyarticular course, present in 52% of patients











8(23.5) 16 21 0.001
8(23.5) 8 10 0.09
4(11.7) 6 17 0.4
3 7.2±4.4 7.3±4.7 6.3±4.3 not
significant
34 0.32±0.36 0.28±0.40 0.26±0.4 not
significant
Figure 1 a and b show Kaplan-Meir survival analysis for the
time to first inactive disease for patients on (Figure 1a) and off
(Figure 1b) therapy. a: Patients on therapy, Kaplan-Meir survival
analysis for the time to first inactive for patients with persistent
oligoarticular arthritis (green line), ERA group (red line) and
polyarticular course arthritis (blue line) for patients on therapy. The
x-axis is time in years and the y-axis shows the percentage of
patients with active arthritis. b: Patients off therapy. Kaplan-Meir
survival analysis for the time to first inactive for patients with
persistent oligoarticular arthritis (green line), ERA group (red line)
and polyarticular course arthritis (blue line) for patients off therapy.
The x-axis is time in years and the y-axis shows the percentage of
patients with active arthritis.
Butbul Aviel et al. Pediatric Rheumatology 2013, 11:11 Page 7 of 8
http://www.ped-rheum.com/content/11/1/11JIA in patients without psoriatic arthritis [24] but slightly
lower than previous studies of JPsA [5,6,10]. Patients
with polyarticular course could be distinguished from
the other subtypes as they had a worse outcome, more
severe clinical course, had more contractures, and lon-
gest mean time to first inactive disease. The pattern
of arthritis differed as they were most likely to have in-
volvement of the small joints of the hands and feet, to
have symmetric disease, to require methotrexate and
least likely to have hip and SI joint involvement. These
findings would suggest that patients with polyarticular
course JPsA form a distinct subset of JPsA patients that
closely resemble patients with polyarticular course JIA
without psoriasis.The most common onset type was oligoarticular arth-
ritis, present in 55% of cases with extension in approxi-
mately 1/3 of cases; an extension rate that is similar to
that seen non-psoriatic oligoarticular onset patients
[24-27]. Similarly, the clinical course of patients with
both persistent oligoarthritis and extended oligoarthritis
more closely resembled JIA clinical sub-types without
psoriasis rather than other JPsA as a whole. At presen-
tation found the frequency of wrist involvement of olgio-
articular patients was closer to the frequency reported in
oligoarticular JIA patients than the reported frequency
of JPsA patients not subdivided [16,28,29]. These fin-
dings suggest that the clinical course of patients with
oligoarticular onset JPsA more closely resembles that
of oligoarticular JIA rather than an unsubseted JPsA
cohort.
A previous study had suggested that there were 2 dis-
tinct groups of patients with JPsA based on age of onset
of disease with the older patients resembling ERA pa-
tients without psoriasis [11]. These older patients gene-
rally resembled the patients in our study with ERA and
psoriasis in the pattern of joint involvement. Acute uve-
itis was only found in this group. Taken together these
findings suggest that these patients older onset male pa-
tients more resemble patients with ERA without pso-
riasis than patients with other courses of JPsA. The
prevalence of HLA-B27 was similar to previous reports
in both ERA and JPsA with ERA features [5,27,30]. We
suggest that this subgroup of patients should be classi-
fied and treated in the same manner as patients with
ERA without psoriasis rather the ILAR current classifi-
cation of undifferentiated. However, long-term studies
are required to confirm this.
The overall outcome of patients in our study was ex-
cellent as during the course of disease 88% achieved in-
active disease on therapy and 50% inactive disease off
therapy. These rates are similar to previously reported
remission rates depending on the definition of remission
and the duration of the follow-up period [31]. The ma-
jority of our patients did not have arthritis at last follow-
up, 30% of patients were without active arthritis off all
medication and only 10% had a contracture. We found
that our patients tended to have linear growth along the
predicted percentiles but that weight percentiles signifi-
cantly increased. The significance of this finding is un-
known but there have been reports that adults with
psoriasis tend to be obese [32].
Conclusions
In conclusion we suggest that JPsA may comprise 4 dis-
tinct groups that are similar to non-JPsA JIA regarding
presentation, disease course, uveitis associations, res-
ponse to treatment and outcome. Future studies are re-
quired to determine if our results are seen in other
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http://www.ped-rheum.com/content/11/1/11cohorts. If other large independent cohorts confirm our
findings then we suggest that the presence of psoriasis
may have little clinical relevance in the outcome and res-
ponse to therapy of children with JIA and therefore we
may consider psoriasis as an extra-articular manifest-
ation seen in JIA, similar to uveitis, rather a feature re-
quiring a distinct classification grouping.
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